Recombinant murine interleukin (IL)-12 (rmIL-12) exhibits antitumor, antiviral, and antimicrobial activities and can modify allergic inflammatory reactions in animal models. Recombinant human IL-12 (rhIL-12) is currently in clinical trials for treatment of cancer, asthma, and viral hepatitis. Principally a phagocyte-derived cytokine, IL-12 targets natural killer cells and T lymphocytes, stimulating their activity and the secretion of interferon (IFN)-γ. An understanding of the toxicology of IL-12, due in part to effects mediated by IFN-γ, has emerged from preclinical safety and mechanistic studies and initial clinical trials. Target organs common to several animal species and humans include the lymphohematopoietic system, intestines, liver, and lung.
Aggarwal BB, Eessalu TE, and Hass PE (1985). Characterization of receptors for human tumor necrosis factor and their regulation by gamma-interferon. Nature318: 665-667.
2.
Anderson TD, Powers GD, Gately MK, Tudor R., Rushton A., and Hayes TJ (1993). Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals. Int. Rev. Exp. Pathol.34A: 58-72.
3.
Bajetta E., Del Vecchio M, Mortarini R., Nadeau R., Rakhit A., Rimassa L., Fowst C., Borri A., Anichini A., and Parmiani G. (1998). Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin. Cancer Res.4: 75-85.
4.
Barbulescu K. , Becker C., Schlaak JF, Schmitt E., Meyer zum Buschenfelde KH, and Neurath MF (1998). IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4- T lymphocytes. J. lmmunol. 160: 3642—3647.
5.
Bellone G. and Trinchieri G. (1994). Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis. J. Immunol.153: 930-937.
6.
Bree AG, Schlerman FJ, Kaviani MD, Hastings RC, Hitz SL, and Goldman SJ (1994). Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem. Biophys. Res. Commun.204: 1150-1157.
7.
Brunda MJ, Luistro L., Rumennik L., Wright RB, Dvorozniak M., Aglione A., Wigginton JM, Wiltrout RH, Hendrzak JA, and Palleroni AV (1996). Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother. Pharmacol.38(suppl.): S16—S21.
8.
Car BD, Eng VM, Schnyder B., Shakhov A., Woerly G., Steckholzer U., Huang S., Aguet M., Anderson TD, and Ryffel B. (1995). IL-12 induced in vivo pathologic alterations are modified in interferon-γ receptor negative mice. Am. J. Pathol.147: 1693-1707.
9.
Chan SH, Perussia B., Gupta JW, Kobayashi M., Posposil M., Young HA, Wolf StF, Young D., Clark SC, and Trinchieri G. (1991). Induction of interferon-γ production by natural killer cell stimulation factor: Characterization of the responder cells and synergy with other inducers. J. Exp. Med.173: 869-869.
10.
Chen L., Chen D., Block E., O'Donnell M., Kufe DW, and Clinton SK (1997). Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J. Immunol.159: 351-359.
11.
Cohen J. (1995). IL-12 deaths: Explanation and a puzzle. Science270: 5238.
12.
Coughlin CM , Wysocka M., Trinchieri G., and Lee WM (1997). The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12 . Cancer Res.57: 2460-2467.
13.
D'Andrea A. , Rengaraju M., Valiante NM, Chehimi J., Kubin M., Aste M., Chan SH, Kobayashi M., Young D., Nickbarg E., Chizzonite R., Wolf SF, and Trinchieri G. (1992). Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J. Exp. Med.176: 1387-1398.
14.
Dranoff G., Crawford AD, Sadelain M., Ream B., Rashid A., Bronson RT, Dickerin GR, Bachurski CJ, Mark EL, Whitsett JA, and Mulligan RC (1994). Involvement of granulocyte-macrophage colony stimulating factor in pulmonary homeostasis. Science264: 713-716.
15.
Emery I., Leclerc C., Sengphommachanh K., Vuitton DA, and Liance M. (1998). In vivo treatment with recombinant IL-12 protects C57BL/6J mice against secondary alveolar echinococcosis. Parasit. Immunol. 20: 81-91.
16.
Eng VM, Car BD, Schnyder B., Lorenz M., Lugli S., Aguet M., Anderson TD, Ryffel B., and Quesniaux Vfj (1995). The stimulatory effects of interleukin-12 on hematopoiesis are inhibited by IL-12 induced IFN-γ in vivo. J. Exp. Med.181: 1893-1898.
17.
Gately MK, Warrier RR, Honasoge S., Carvajal DM, Faherty DA, Connaughton SE, Anderson TD, Sarmiento U., Hubbard BR, and Murphy M. (1994). Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. Immunol.6: 157-167.
18.
Golab J., Stoklosa T., Zagozdzon R., Kaca A., Giermasz A., Pojda Z., Machaj E., Dabrowska A., Feleszko W., Lasek W., Iwan-Osiecka A., and Jakóbisiak M. (1998). G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. Ann. Oncol.9: 63-69.
19.
Golab J., Zagozdzon R., Stoklosa T., Lasek W., Jakóbisiak M., Pojda Z., and Machaj E. (1998). Erythropoietin prevents the development of interleukin-12-induced anemia and thrombocytopenia but does not decrease its antitumor activity in mice. Blood91: 4387-4388.
20.
Greenberger MJ, Kunkel SL, Strieter RM, Lukacs NW, Bramson J., Gauldie J., Graham FL, Hitt M., Danforth JM, and Standiford TJ (1996). IL-12 gene therapy protects mice in lethal Klebsiella pneumonia infection . J. Immunol.157: 3006-3012.
21.
Guardiola J. and Maffei A. (1993). Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases . Crit. Rev. Immunol.13: 247-268.
22.
Hall LB, Lipman JM, and Anderson TD (1993). Skeletal muscle changes in mice treated with recombinant murine interleukin 12. Toxicol. Pathol.21: 593.
23.
Hall LB, Slater C., Catala AR, and Lipman JM (1998). The toxicologic profile of Ro 24-7472 (recombinant human interleukin-12) in guinea pigs and cynomolgus monkeys following two weeks of subcutaneous administration. Toxicol. Pathol.26: 835 (abstract).
24.
Hall SS (1995). IL-12 at the crossroads. Science268: 1432-1435.
25.
Hayes-Donelly L., Erickson J., Mason L., Clark E., and Bouchard P. (1998). Characterization of IL-12-induced pulmonary lesions in IFNγ receptor knock out mice. FASEB J. 12: A789.
26.
Hilkins C., Snijders A., Vermeulen H., van der Meide P., Wierenga E., and Kapsenberg M. (1996). Accessory cell-derived interleukin-12 and prostaglandin E2 determine the level of interferon-γ produced by activated human CD4 T cells. Ann. N. Y. Acad. Sci.795: 349-353.
27.
Huang S., Hendriks W., Althage A., Hemmi S., Blüthmann H., Kamijo R., Vilcek R., Zinkernagel RM, and Aguet M. (1993). Immune response in mice that lack the interferon-γ receptor. Science259: 1742-1745.
28.
Jacobsen SE , Okkenhaug C., Myklebust J., Veiby OP, and Lyman SD (1995). The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells: In vitro synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. J. Exp. Med.181: 1357-1363.
29.
Kennedy BP, Payette P., Mudgett J., Vadas P., Pruzanski W., Kwan M., Tang C., Rancourt DE, and Cromlish WA (1995). A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem.270: 22378-22385.
30.
Kobayashi K. , Kasama T., Yamazaki J., Hosaka M., Katsura T., Mochizuki T., Soejima K., and Nakamura RM (1995). Protection of mice from Mycobacterium avium infection by recombinant interleukin-12 . Antimicrob. Agents Chemother.39: 1369—1371.
31.
Kobayashi M. , Fitz L., Ryan M., Hewick RM, Clark SC, Chan S., Loudon R., Sherman F., Perussia B., and Trinchieri G. (1989). Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes . J. Exp. Med.170: 827-845.
32.
Kurzrock R. , Rosenblum MG, Sherwin SA, Rios A., Talpaz M., Quesada JR, and Gutterman JU (1985). Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res.45: 2866-2872.
33.
Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G., At-kins MB, Sosman JA, Dutcher JP, Vogelzang NJ, and Ryan JL (1997). Effects of single-dose interleukin-12 exposure on interleukin- 12—associated toxicity and interferon-gamma production . Blood90: 2541-2548.
34.
Liu W. and Kurlander RJ (1995). Analysis of the interrelationship between IL-12, TNF-alpha, and IFN-gamma production during murine listeriosis. Cell. Immunol.163: 260-267.
35.
Lotze MT, Trinchieri G, Gately M, and Wolf S (eds) (1996). Interleukin 12: Cellular and molecular immunology of an important regulatory cytokine . Ann. N. Y. Acad. Sci.795: 1-454.
36.
Ma X., Chow JM, Gri G., Carra G., Gerosa F., Wolf SF, Dzialo R., and Trinchieri G. (1996). The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med.183: 147-157.
37.
Malfait AM, Butler DM, Presky DH, Maini RN, Brennan FM, and Feldmann M. (1998). Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin. Exp. Immunol.111: 377-383.
38.
Morris SC, Madden KB, Adamovicz JJ, Gause WC, Hubbard BR, Gately MK, and Finkelman FD (1994). Effects of IL-12 on in vivo cytokine gene expression and Ig isotope selection. J. Immunol.152: 1047-1056.
39.
Orange JS, Salazar-Mather TP, Opal SM, Spencer RL, Miller AH, McEwen BS, and Biron CA (1995). Mechanism of interleukin 12-mediated toxicities during experimental viral infections: Role of tumor necrosis factor and glucocorticoids . J. Exp. Med.181: 901-914.
40.
Ozmen L., Aguet M., Trinchieri G., and Garotta G. (1995). The in vivo antiviral activity of interleukin-12 is mediated by gamma interferon. J. Virol.69: 8147-8150.
41.
Paul WE and Seder RA (1994). Lymphocyte responses and cytokines. Cell76: 241-251.
42.
Ploemacher RE, van Soest PL, Boudewijn A., and Neben S. (1993). Interleukin-12 enhances interleukin-3 dependent multilineage hematopoietic colony formation stimulated by interleukin-11 or Steel factor. Leukemia7: 1374-1380.
43.
Romani L., Puccetti P., and Bistoni F. (1997). Interleukin-12 in infectious diseases. Clin. Microbiol. Rev.10: 611-636.
44.
Ruggiero V. , Tavernier J., Fiers W., and Baglioni C. (1986). Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma . J. Immunol.136: 2445-2450.
45.
Sarmiento UM , Riley JH, Knaack PA, Lipman JM, Becker JM, Gately MK, Chizzonite R., and Anderson TD (1994). Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab. Invest.71: 862-873.
46.
Smith T., Hewson AK, Kingsley CI, Leonard JP, and Cuzner ML (1997). Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. Am. J. Pathol.150: 1909-1917.
47.
Stanley E., Lieschke GJ, Grail D., Metcalf D., Hodgson G., Gall Jam, Maher DW, Cebon J., Sinickas V., and Dunn AR (1994). Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. USA91: 5592-5596.
48.
Stern AS, Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, Wolitzky AG, Familletti PC, Stremlo DL, Truitt T., Chizzonite R., and Gately MK (1990). Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells . Proc. Natl. Acad. Sci. USA87: 6808-6802.
49.
Sur S., Lam J., Bouchard P., Sigounas A., Holbert D., and Metzger WJ (1996). Immunomodulatory effects of IL-12 on allergic lung inflammation depend on timing of doses. J. Immunol.157: 4173-4180.
50.
Tare NS, Bowen S., Warrier RR, Carvajal DM, Benjamin WR, Riley JH, Anderson TD, and Gately MK (1995). Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J. Interferon Cytokine Res.15: 377-383.
51.
Terrell TG and Green JD (1993). Comparative pathology of recombinant murine interferon-γ in mice and recombinant human interferon-γ in cynomolgus monkeys. Int. Rev. Exp. Pathol.34B: 73-101.
52.
Trembleau S. , Germann T., Gately MK, and Adorini L. (1995). The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol. Today17: 214-217.
53.
Trembleau S. , Penna G., Bosi E., Mortara A., Gately MK, and Adorini L. (1995). Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice . J. Exp. Med.181: 817-821.
54.
Trinchieri G. (1993). Interleukin-12 and its role in the generation of TH1 cells. Immunol. Today14: 335-358.
55.
Trinchieri G. (1995). Interleukin-12 and interferon-gamma. Do they always go together?Am. J. Pathol.147: 1534-1538.
56.
Trinchieri G., Rengaraju M., D'Andrea A., Valiante NM, Kubin M., Aste M., and Chehimi J. (1993). Producer cells of interleukin-12 . Immunol. Today14: 237-238.
57.
Tsung K., Meko JB, Tsung YL, Peplinski GR, and Norton JA (1988). Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J. Immunol.160: 1369-1377.
58.
Williamson E., Garside P., Bradly JA, and Mowat AM (1996). IL-12 is a central mediator of acute graft-versus-host disease in mice. J. Immunol.157: 689-699.
59.
Wolf SF, Temple PA, Kobayashi M., Young D., Dicig M., Lowe L., Dzialo R., Fitz L., Ferenz C., Hewick RM, Kelleher K., Herrman SH, Clark SC, Azzoni L., Chan SH, Trinchieri G., and Perussia B. (1991). Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol.146: 3074-3081.
60.
Zhan Y. and Cheers C. (1995). Endogenous interleukin-12 is involved in resistance to Brucella abortus infection. Infect. Immun.63: 1387-1390.
61.
Zhang T., Kawakami K., Qureshi MH, Okamura H., Kurimoto M., and Saito A. (1997). Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect. lmmun. 65: 3594-3599.
62.
Zisman DA, Kunkel SL, Strieter RM, Gauldie J., Tsai WC, Bramson J., Wilkowski JM, Bucknell KA, and Standiford TJ (1997). Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs clearance in murine Escherichia coli peritoneal sepsis . Shock8: 349-356.
